Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 June 2025 | Story Onthatile Tikoe | Photo Supplied
Logan James
Logan W. James, UFS alumnus and breakout star of Binnelanders Season 15, proudly waves the Kovsie flag as he steps into his first national television role.

University of the Free State (UFS) alumnus Logan W James made his national television debut in Season 15 of kykNET’s long-running medical drama, Binnelanders. Streaming on Showmax from 4 June 2025, the latest season introduces Logan in a role that delivers high drama, high energy, and a fresh wave of talent rooted in the Free State.

 

From campus to camera

Born and bred in Bloemfontein, Logan’s rise from student theatre to the small screen is a story stitched together by grit, passion, and a deep love for performance. A former learner of Grey College and a proud Kovsie, Logan honed his craft at the University of the Free State, where he quickly became known for his magnetic stage presence and commitment to his roles.

From standout performances in Everyman, How to Wuzz, and Run for Your Wife to unforgettable moments during UFS’s annual Africa Day showcases, Logan carved out a name for himself as a rising star on campus – one performance at a time.

 

A dream years in the making

Now based in Johannesburg, Logan is stepping into a new kind of spotlight. He plays Le Roux Snyman - a thrill-seeking, motocross-riding character with a bold facade and hidden depths.

“Le Roux is full of energy and contradictions,” Logan says. “He lives for extreme sports and adrenaline, but there’s a much softer, more vulnerable side he doesn’t often show. What excites me is exploring both boldness and fragility in the same breath - it’s something I’ve never quite done before.”

Though this may be Logan’s TV debut, stepping onto the Binnelanders set felt strangely familiar.

“I used to watch Binnelanders at my grandmother’s house,” he recalls. “Never in my wildest dreams did I imagine I’d one day be part of the cast. It feels like a full-circle moment - a dream realised. The journey here wasn’t straightforward, but seeing it come to life like this is an incredible blessing.”

 

The foundation of theatre

Logan credits his Bloemfontein theatre roots as the foundation of his acting journey. “Theatre taught me discipline, presence, and heart,” he says. “On stage, there are no second takes. You have to show up, fully and honestly, every time. That kind of intensity trains you not as a performer, but as a professional.

These lessons continue to shape how he approaches his work today. “Kindness and professionalism – those are the two things I carry into every production,” he adds.

 

Big city, bigger lessons

The move from Bloem’s close-knit creative community to the bustling entertainment industry in Johannesburg came with new challenges – and new lessons.

“In Joburg, you quickly realise just how much talent is out there,” Logan says. “It forced me to embrace what makes me unique, rather than compare myself to others. Real passion – not the pursuit of fame – is what carries you through the tough times. If you’re chasing the art, not the spotlight, you’ll find purpose, even when things get hard.”

 

A voice for regional talent

Logan’s journey is not just a personal triumph – it’s also a win for regional talent. As a Free State-born actor breaking into the national scene, he is part of a growing wave of creatives proving that national recognition is possible from anywhere.

“To go from student theatre to national TV is a leap that’s both terrifying and thrilling,” Logan reflects. “But it's proof that consistent hard work, staying true to your craft, and trusting the process can open doors you once only dreamed of.”

 

Ready for the spotlight

With his first episode having aired on 4 June, audiences were treated to a performance that was rich with energy and layered with emotion.

“There’s a lot of growth ahead - for Le Roux and for me,” Logan shares. “I’m looking forward to every moment of it. I can’t wait for South Africa to meet him.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept